Gilmore O'Neill, Editas Medicine CEO

With Ver­tex and CRISPR some 30 pa­tients in, Ed­i­tas moves for­ward in sick­le cell pa­tients af­ter FDA lifts hold

With gene ther­a­pies for sick­le cell dis­ease prov­ing all the rage, one com­pa­ny is get­ting its FDA-im­posed chains re­moved.

Ed­i­tas Med­i­cine an­nounced Wednes­day that the FDA lift­ed a par­tial hold on an ear­ly-stage study for its sick­le cell ther­a­py. Reg­u­la­tors had placed the hold on the com­pa­ny’s ED­IT-301 pro­gram and asked it to de­vel­op a new po­ten­cy as­say, com­pa­ny spokesper­son Cristi Bar­nett tells End­points News. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.